Letter to the Editor
Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11 cases and review of the literature

https://doi.org/10.1016/j.ejim.2017.11.014Get rights and content

Section snippets

Conflict of interest statement

The authors report no relationships that could be construed as a conflict of interest.

Acknowledgment

We thank C. Cassius, T. Legris, M. Le Besnerais, AS. Morin, and A. Mekinian for their help to collect clinical data.

References (10)

  • I. Martin-Garrido et al.

    Pneumocystis pneumonia in patients treated with rituximab

    Chest J

    (1 juill 2013)
  • R.N. Wickramasekaran et al.

    The changing trends and profile of pneumocystosis mortality in the United States, 1999–2014

    Mycoses

    (2017)
  • F.E. Lund et al.

    B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection

    J Immunol

    (2006)
  • H. Andersson et al.

    Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease

    Rheumatology (Oxford)

    (2015)
  • E. Besada et al.

    Should Pneumocystis jirovecii prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

    Clin Rheumatol

    (nov 2013)
There are more references available in the full text version of this article.

Cited by (14)

  • Pulmonary Infiltrates

    2022, Infectious Complications in Biologic and Targeted Therapies
View all citing articles on Scopus
View full text